{"absolute_url": "/opinion/2673211/teva-pharmaceuticals-usa-inc-v-sandoz-inc/", "blocked": false, "citation": {"case_name": "Teva Pharmaceuticals USA, Inc. v. Sandoz, Inc.", "docket_number": "13A1003 (13-854)", "document_uris": ["/api/rest/v2/document/2673211/"], "federal_cite_one": null, "federal_cite_three": null, "federal_cite_two": null, "id": 2645984, "lexis_cite": null, "neutral_cite": null, "resource_uri": "/api/rest/v2/citation/2645984/", "scotus_early_cite": null, "specialty_cite_one": null, "state_cite_one": null, "state_cite_regional": null, "state_cite_three": null, "state_cite_two": null, "westlaw_cite": null}, "citation_count": 0, "court": "/api/rest/v2/jurisdiction/scotus/", "date_blocked": null, "date_filed": "2014-04-18", "date_modified": "2014-10-30T00:59:58.748308", "docket": "/api/rest/v2/docket/261780/", "download_url": "http://www.supremecourt.gov/opinions/13pdf/13a1003_5h26.pdf", "extracted_by_ocr": false, "html": null, "html_lawbox": null, "html_with_citations": "<pre class=\"inline\">                        Cite as: 572 U. S. ____ (2014)                              1\n\n                             Opinion in Chambers\n\n     NOTICE: This opinion is subject to formal revision before publication in the\n     preliminary print of the United States Reports. Readers are requested to\n     notify the Reporter of Decisions, Supreme Court of the United States, Wash-\n     ington, D. C. 20543, of any typographical or other formal errors, in order\n     that corrections may be made before the preliminary print goes to press.\n\n\nSUPREME COURT OF THE UNITED STATES\n                                   _________________\n\n                            No. 13A1003 (13–854)\n                                   _________________\n\n\n     TEVA PHARMACEUTICALS USA, INC., ET AL.\n             v. SANDOZ, INC., ET AL.\n       ON APPLICATION TO RECALL AND STAY MANDATE\n                                 [April 18, 2014]\n\n   CHIEF JUSTICE ROBERTS, Circuit Justice.\n   The application to recall and stay the mandate of the\nUnited States Court of Appeals for the Federal Circuit, see\n723 F. 3d 1363 (2013), is denied. To obtain such relief,\napplicant Teva Pharmaceuticals USA, Inc., must demon-\nstrate (1) a “reasonable probability” that this Court will\ngrant certiorari, (2) a “fair prospect” that the Court will\nreverse the decision below, and (3) a “likelihood that ir-\nreparable harm [will] result from the denial of a stay.”\nMaryland v. King, 567 U. S. ___, ___ (2012) (ROBERTS, C.\nJ., in chambers) (slip op., at 1) (internal quotation marks\nomitted). Teva has of course satisfied the first require-\nment, and has also shown a fair prospect of success on the\nmerits. I am not convinced, however, that it has shown a\nlikelihood of irreparable harm from denial of a stay.\nRespondents acknowledge that, should Teva prevail in\nthis Court and its patent be held valid, Teva will be able to\nrecover damages from respondents for past patent in-\nfringement. See Brief in Opposition 25–28. Given the\navailability of that remedy, the extraordinary relief that\nTeva seeks is unwarranted.\n                                             It is so ordered.\n</pre>", "id": 2673211, "judges": "", "local_path": "pdf/2014/04/18/teva_pharmaceuticals_usa_inc._v._sandoz_inc..pdf", "nature_of_suit": "", "plain_text": "                        Cite as: 572 U. S. ____ (2014)                              1\n\n                             Opinion in Chambers\n\n     NOTICE: This opinion is subject to formal revision before publication in the\n     preliminary print of the United States Reports. Readers are requested to\n     notify the Reporter of Decisions, Supreme Court of the United States, Wash-\n     ington, D. C. 20543, of any typographical or other formal errors, in order\n     that corrections may be made before the preliminary print goes to press.\n\n\nSUPREME COURT OF THE UNITED STATES\n                                   _________________\n\n                            No. 13A1003 (13–854)\n                                   _________________\n\n\n     TEVA PHARMACEUTICALS USA, INC., ET AL.\n             v. SANDOZ, INC., ET AL.\n       ON APPLICATION TO RECALL AND STAY MANDATE\n                                 [April 18, 2014]\n\n   CHIEF JUSTICE ROBERTS, Circuit Justice.\n   The application to recall and stay the mandate of the\nUnited States Court of Appeals for the Federal Circuit, see\n723 F. 3d 1363 (2013), is denied. To obtain such relief,\napplicant Teva Pharmaceuticals USA, Inc., must demon-\nstrate (1) a “reasonable probability” that this Court will\ngrant certiorari, (2) a “fair prospect” that the Court will\nreverse the decision below, and (3) a “likelihood that ir-\nreparable harm [will] result from the denial of a stay.”\nMaryland v. King, 567 U. S. ___, ___ (2012) (ROBERTS, C.\nJ., in chambers) (slip op., at 1) (internal quotation marks\nomitted). Teva has of course satisfied the first require-\nment, and has also shown a fair prospect of success on the\nmerits. I am not convinced, however, that it has shown a\nlikelihood of irreparable harm from denial of a stay.\nRespondents acknowledge that, should Teva prevail in\nthis Court and its patent be held valid, Teva will be able to\nrecover damages from respondents for past patent in-\nfringement. See Brief in Opposition 25–28. Given the\navailability of that remedy, the extraordinary relief that\nTeva seeks is unwarranted.\n                                             It is so ordered.\n", "precedential_status": "In-chambers", "resource_uri": "/api/rest/v2/document/2673211/", "sha1": "109f6aadec7067a8b78502c183cfa4746b917826", "source": "C", "time_retrieved": "2014-05-09T18:27:25.135205"}